
  
    
      
        Background_NNP
        Renal_NNP transplant_NN recipients_NNS are_VBP at_IN high_JJ risk_NN for_IN
        post-transplant_JJ diabetes_NN mellitus_JJ ._. However_RB ,_, information_NN on_IN
        the_DT incidence_NN and_CC risk_NN factors_NNS for_IN diabetic_JJ ketoacidosis_NNS
        (_( diabetic_JJ ketoacidosis_NNS )_) after_IN solid_JJ organ_NN transplantation_NN
        has_VBZ been_VBN limited_VBN to_TO single-center_JJ reports_NNS ._. [_NN 1_CD 2_CD 3_CD 4_CD ]_NN
        There_EX are_VBP even_RB fewer_JJR reports_NNS on_IN hyperglycemic_JJ hyperosmolar_NN
        syndrome_NN (_( hyperglycemic_JJ hyperosmolar_NN syndrome_NN ,_, previously_RB
        called_VBN nonketotic_JJ hyperosomolar_NN coma_NN )_) after_IN renal_JJ
        transplantation_NN ._. [_NN 5_CD 6_CD ]_NN Recently_RB ,_, post-transplant_JJ diabetes_NN
        mellitus_JJ has_VBZ been_VBN associated_VBN with_IN tacrolimus_JJ use_NN in_IN renal_JJ
        transplant_NN recipients_NNS with_IN hepatitis_NNP C_NNP antibody_NN positivity_NN ,_,
        [_NN 7_CD ]_NN although_IN this_DT experience_NN is_VBZ not_RB universal_JJ ._. [_NN 8_CD ]_NN Only_RB
        one_CD report_NN of_IN diabetic_JJ ketoacidosis_NNS associated_VBN with_IN
        tacrolimus_JJ use_NN in_IN a_DT patient_NN without_IN a_DT prior_JJ history_NN of_IN
        diabetes_NN has_VBZ so_RB far_RB been_VBN reported_VBN ._. [_NN 9_CD ]_NN Tacrolimus_NNP was_VBD
        approved_VBN by_IN the_DT FDA_NNP for_IN use_NN in_IN kidney_NN transplantation_NN in_IN
        1997_CD ._. We_PRP therefore_RB performed_VBD a_DT historical_JJ cohort_NN study_NN of_IN
        the_DT United_NNP States_NNPS Renal_NNP Data_NNP System_NNP (_( USRDS_NNP )_) Renal_NNP
        transplant_NN population_NN ._. Our_PRP$ objectives_NNS were_VBD to_TO determine_VB the_DT
        incidence_NN ,_, risk_NN factors_NNS ,_, and_CC mortality_NN associated_VBN with_IN
        hospitalizations_NNS for_IN diabetic_JJ ketoacidosis_NNS (_( primary_JJ
        hospitalization_NN discharge_NN ICD_NNP 9_CD code_NN 250_CD ._. 1_LS x_SYM )_) and_CC
        hyperglycemic_JJ hyperosmolar_NN syndrome_NN (_( ICD_NNP 9_CD code_NN 250_CD ._. 2_LS x_SYM )_)
        occurring_VBG after_IN renal_JJ transplantation_NN ._.
      
      
        Methods_NNP
        
          Patient_NNP Population_NNP
          This_DT study_NN used_VBD data_NNS from_IN the_DT United_NNP States_NNPS Renal_NNP Data_NNP
          System_NNP (_( USRDS_NNP )_) ,_, using_VBG standard_JJ analysis_NN files_NNS (_( SAF_NNP 's_POS )_) as_IN
          of_IN May_NNP 2000_CD ._. The_DT USRDS_NNP ,_, indirectly_RB mandated_VBN by_IN federal_JJ
          law_NN ,_, incorporates_VBZ baseline_NN and_CC follow-up_JJ demographic_JJ and_CC
          clinical_JJ data_NNS on_IN all_DT patients_NNS receiving_VBG end_NN stage_NN renal_JJ
          disease_NN (_( ESRD_NNP )_) therapy_NN in_IN the_DT United_NNP States_NNPS ._. ESRD_NNP therapy_NN
          includes_VBZ hemodialysis_NNS ,_, peritoneal_JJ dialysis_NN ,_, and_CC renal_JJ
          transplantation_NN ._. Because_IN patient_NN entry_NN into_IN the_DT USRDS_NNP is_VBZ
          linked_VBN to_TO Medicare_NNP reimbursement_NN ,_, and_CC ESRD_NNP services_NNS are_VBP
          expensive_JJ ,_, very_RB few_JJ transplant_NN patients_NNS are_VBP not_RB
          represented_VBN in_IN the_DT database_NN ._. The_DT variables_NNS included_VBN in_IN
          the_DT USRDS_NNP standard_JJ analysis_NN files_NNS (_( SAF_NNP )_) ,_, as_RB well_RB as_IN data_NNS
          collection_NN methods_NNS and_CC validation_NN studies_NNS ,_, are_VBP listed_VBN at_IN
          the_DT USRDS_NNP website_NN ,_, under_IN '_POS Researcher_NNP 's_POS Guide_NNP to_TO the_DT USRDS_NNP
          Database_NNP '_POS ,_, Section_NNP E_NNP ,_, '_'' Contents_NNP of_IN all_PDT the_DT SAF_NNP 's_POS ,_,
          http_NN :_: /_NN /_NN www_NN ._. usrds_NNS ._. organd_NN published_VBN in_IN the_DT USRDS_NNP ._. The_DT
          demographics_NNS of_IN the_DT renal_JJ transplant_NN population_NN have_VBP been_VBN
          previously_RB described_VBN (_( 2001_CD USRDS_NNP report_NN )_) ._. SAF_NNP ._. TXUNOS_NNP was_VBD
          used_VBN as_IN the_DT primary_JJ dataset_NN ,_, and_CC merged_VBD with_IN variables_NNS
          from_IN SAF_NNP ._. HOSP_NNP for_IN hospitalization_NN data_NNS ,_, and_CC SAF_NNP ._. PATIENTS_NNP
          for_IN dates_NNS and_CC causes_NNS of_IN death_NN as_RB well_RB as_IN causes_NNS of_IN renal_JJ
          disease_NN ,_, as_RB previously_RB reported_VBD ._. [_NN 10_CD 11_CD 12_CD ]_NN Patient_NNP
          characteristics_NNS and_CC treatment_NN factors_NNS were_VBD those_DT at_IN the_DT
          date_NN of_IN transplant_NN ._. Recipients_NNP of_IN organs_NNS other_JJ than_IN
          kidneys_NNS were_VBD excluded_VBN ._.
        
        
          Outcome_NNP Definition_NNP
          We_PRP conducted_VBD a_DT historical_JJ cohort_NN study_NN of_IN the_DT
          incidence_NN ,_, risk_NN factors_NNS and_CC associated_VBN patient_NN survival_NN
          for_IN hospitalized_VBN cases_NNS of_IN diabetic_JJ ketoacidosis_NNS (_( based_VBN on_IN
          International_NNP Classification_NNP of_IN Diseases-_NNP 9_CD th_NN Modification_NNP
          Diagnosis_NNP Codes_NNP (_( ICD_NNP 9_CD )_) at_IN hospital_NN discharge_NN for_IN diabetic_JJ
          ketoacidosis_NNS ,_, 250_CD ._. 1_LS x_SYM ,_, and_CC hyperosmotic_JJ hyperosmolar_NN
          syndrome_NN (_( also_RB known_VBN as_IN non-ketotic_JJ hyperosmolar_NN coma_NN )_) ,_,
          ICD_NNP 9_CD code_NN 250_CD ._. 2_LS x_SYM ,_, as_IN a_DT primary_JJ discharge_NN diagnosis_NN in_IN
          renal_JJ transplant_NN recipients_NNS ._. The_DT first_JJ hospitalization_NN
          for_IN diabetic_JJ ketoacidosis_NNS after_IN the_DT first_JJ solitary_JJ renal_JJ
          transplant_NN (_( thus_RB excluding_VBG kidney-pancreas_JJ or_CC other_JJ
          multiple_JJ transplants_NNS )_) for_IN a_DT given_VBN individual_JJ occurring_VBG on_IN
          or_CC after_IN 1_CD July_NNP 1994_CD and_CC before_IN 1_CD July_NNP 1998_CD (_( which_WDT
          included_VBD repeat_NN transplants_NNS )_) ,_, with_IN follow-up_JJ time_NN
          truncated_JJ at_IN three_CD years_NNS was_VBD counted_VBN in_IN analysis_NN ._.
          Hospitalizations_NNP were_VBD chosen_VBN because_IN they_PRP were_VBD more_RBR
          accessible_JJ in_IN the_DT database_NN and_CC less_RBR subject_JJ to_TO
          interpretation_NN than_IN outpatient_NN cases_NNS of_IN diabetic_JJ
          ketoacidosis_NNS ,_, especially_RB since_IN the_DT USRDS_NNP database_NN has_VBZ no_DT
          information_NN on_IN confirmatory_NN studies_NNS ._. Hospitalization_NNP data_NNS
          for_IN transplant_NN recipients_NNS may_MD be_VB unreliable_JJ after_IN the_DT
          patient_NN has_VBZ survived_VBN â‰¥_NN 3_CD years_NNS post_NN transplant_NN ,_, when_WRB
          hospitalization_NN reporting_VBG to_TO Medicare_NNP for_IN patients_NNS 65_CD
          years_NNS or_CC younger_JJR is_VBZ no_RB longer_RB required_VBN ._. However_RB ,_, Medicare_NNP
          reporting_NN starts_VBZ immediately_RB after_IN transplant_NN ,_, regardless_RB
          of_IN preceding_VBG dialysis_NN status_NN ._. All_DT hospitalizations_NNS with_IN a_DT
          primary_JJ discharge_NN diagnosis_NN for_IN diabetic_JJ ketoacidosis_NNS
          were_VBD extracted_VBN from_IN SAF_NNP ._. HOSP_NNP ,_, merged_VBD with_IN the_DT transplant_NN
          file_NN using_VBG unique_JJ identifiers_NNS ,_, and_CC hospitalizations_NNS
          outside_IN the_DT range_NN of_IN the_DT study_NN period_NN were_VBD excluded_VBN ._.
          Hospitalizations_NNP for_IN diabetic_JJ ketoacidosis_NNS occurring_VBG at_IN
          any_DT time_NN after_IN renal_JJ transplant_NN ,_, including_VBG after_IN graft_NN
          failure_NN (_( censored_VBN for_IN patient_NN death_NN )_) ,_, were_VBD counted_VBN in_IN
          analysis_NN ._.
        
        
          Variables_NNP used_VBD in_IN analysis_NN
          The_DT independent_JJ associations_NNS between_IN patient_NN factors_NNS
          and_CC hospitalizations_NNS for_IN diabetic_JJ ketoacidosis_NNS were_VBD
          examined_VBN using_VBG multivariate_NN analysis_NN with_IN stepwise_NN Cox_NNP
          Regression_NNP including_VBG recipient_NN and_CC donor_NN age_NN ,_, recipient_JJ
          race_NN ,_, gender_NN ,_, weight_NN ,_, pretransplant_NN dialysis_NN (_( yes_UH /_NN no_DT )_) ,_,
          duration_NN of_IN dialysis_NN prior_RB to_TO transplantation_NN ,_, total_JJ
          follow-up_JJ time_NN ,_, recipient_JJ hepatitis_NNP C_NNP serology_NN ,_, donor_NN
          cytomegalovirus_JJ serology_NN ,_, pre-transplant_JJ dialysis_NN
          (_( yes_UH /_NN no_DT )_) ,_, rejection_NN (_( either_CC treatment_NN or_CC diagnosis_NN )_)
          occurring_VBG at_IN any_DT time_NN in_IN the_DT study_NN period_NN ,_, induction_NN
          antibody_NN therapy_NN ,_, maintenance_NN immunosuppressive_JJ
          medications_NNS at_IN time_NN of_IN discharge_NN after_IN transplant_NN
          surgery_NN ,_, graft_NN loss_NN ,_, and_CC cause_NN of_IN end_NN stage_NN renal_JJ disease_NN
          (_( ESRD_NNP ,_, either_CC diabetes_NN or_CC other_JJ causes_NNS )_) ._. The_DT USRDS_NNP does_VBZ
          not_RB reliably_RB distinguish_VB between_IN type_NN I_PRP and_CC type_NN II_NNP
          diabetes_NN ._. Previous_JJ investigators_NNS have_VBP used_VBN the_DT occurrence_NN
          of_IN diabetes_NN in_IN patients_NNS younger_JJR than_IN age_NN 40_CD as_IN a_DT
          surrogate_NN for_IN type_NN I_PRP diabetes_NN ._. (_( 13_CD )_) However_RB ,_, given_VBN the_DT
          growing_VBG frequency_NN of_IN type_NN II_NNP diabetes_NN in_IN younger_JJR
          patients_NNS ,_, (_( 14_CD )_) we_PRP did_VBD not_RB think_VB this_DT assumption_NN would_MD be_VB
          valid_JJ in_IN more_RBR recent_JJ years_NNS of_IN the_DT database_NN ._. We_PRP therefore_RB
          chose_VBD to_TO group_VB all_DT patients_NNS with_IN ESRD_NNP due_JJ to_TO diabetes_NN
          together_RB ._. Diabetes_NNP as_IN a_DT comorbid_NN condition_NN at_IN the_DT time_NN of_IN
          listing_NN for_IN transplant_NN was_VBD also_RB used_VBN as_IN a_DT variable_NN ,_,
          although_IN information_NN on_IN this_DT variable_NN was_VBD missing_VBG or_CC
          unknown_JJ for_IN 23_CD ._. 3_LS %_NN of_IN patients_NNS (_( Tables_NNP 1_CD ,_, 2_CD ,_, 3_LS )_) ._.
          Information_NNP on_IN insulin_NN dependence_NN was_VBD missing_VBG for_IN 81_CD %_NN of_IN
          patients_NNS ,_, however_RB ,_, and_CC was_VBD not_RB considered_VBN reliable_JJ for_IN
          analysis_NN ._. Episodes_NNP of_IN rejection_NN were_VBD not_RB restricted_VBN to_TO
          those_DT occurring_VBG in_IN the_DT first_JJ year_NN ,_, in_IN contrast_NN to_TO studies_NNS
          of_IN allograft_NN function_NN ,_, since_IN there_EX is_VBZ no_DT evidence_NN that_IN
          late_JJ (_( vs_NNS ._. early_JJ )_) rejection_NN has_VBZ a_DT different_JJ impact_NN on_IN
          diabetic_JJ ketoacidosis_NNS ._. However_RB ,_, only_RB episodes_NNS of_IN diabetic_JJ
          ketoacidosis_NNS or_CC hyperglycemic_JJ hyperosmolar_NN syndrome_NN
          occurring_VBG after_IN the_DT approximate_JJ date_NN of_IN rejection_NN were_VBD
          used_VBN in_IN assessing_VBG the_DT association_NN of_IN rejection_NN with_IN
          diabetic_JJ ketoacidosis_NNS or_CC hyperglycemic_JJ hyperosmolar_NN
          syndrome_NN ._. The_DT total_JJ cumulative_JJ dose_NN of_IN prednisone_NN was_VBD not_RB
          available_JJ in_IN the_DT USRDS_NNP ._. UNOS_NNP tracks_VBZ the_DT numbers_NNS of_IN days_NNS
          of_IN prednisone_NN administered_VBN prior_RB to_TO initial_JJ hospital_NN
          discharge_NN ;_: however_RB ,_, values_NNS were_VBD missing_VBG for_IN >_NN 90_CD %_NN of_IN
          patients_NNS in_IN both_DT databases_NNS and_CC could_MD not_RB be_VB used_VBN as_IN a_DT
          covariate_NN in_IN the_DT above_JJ analyses_NNS ._. Maintenance_NNP
          immunosuppressive_JJ medication_NN use_NN ,_, in_IN particular_JJ
          cyclosporine_NN and_CC tacrolimus_JJ ,_, at_IN the_DT time_NN of_IN discharge_NN
          after_IN transplantation_NN was_VBD also_RB analyzed_VBN as_IN a_DT preexisting_VBG
          covariate_NN ._. Information_NNP on_IN use_NN of_IN medications_NNS (_( other_JJ than_IN
          immunosuppressive_JJ medications_NNS )_) ,_, alcohol_NN ,_, tobacco_NN ,_, or_CC
          radiologic_JJ procedures_NNS was_VBD not_RB available_JJ ._. Dialysis_NNP
          modality_NN was_VBD obtained_VBN from_IN the_DT file_NN Sdiabetic_NNP
          ketoacidosis_NNS ._. RXHIST_NNP 60_CD ._. The_DT initial_JJ dialysis_NN modality_NN a_DT
          patient_NN used_VBN for_IN at_IN least_JJS 60_CD days_NNS after_IN presentation_NN to_TO
          end_VB stage_NN renal_JJ disease_NN and_CC prior_RB to_TO renal_JJ
          transplantation_NN was_VBD utilized_JJ in_IN intention_NN to_TO treat_VB
          fashion_NN ._.
        
        
          Survival_NNP Times_NNP
          For_IN time_NN to_TO diabetic_JJ ketoacidosis_NNS ,_, survival_NN time_NN was_VBD
          defined_VBN as_IN the_DT time_NN from_IN first_JJ renal_JJ transplant_NN until_IN
          hospitalization_NN for_IN diabetic_JJ ketoacidosis_NNS ,_, with_IN patients_NNS
          censored_VBN at_IN death_NN ,_, loss_NN to_TO follow-up_JJ ,_, or_CC end_NN of_IN the_DT
          study_NN ._. Since_IN the_DT most_RBS recent_JJ hospitalization_NN date_NN was_VBD 31_CD
          December_NNP ,_, 1999_CD ,_, this_DT was_VBD considered_VBN the_DT end_NN of_IN the_DT study_NN
          period_NN for_IN this_DT measurement_NN ._. Survival_NNP time_NN was_VBD defined_VBN as_IN
          the_DT time_NN from_IN the_DT date_NN of_IN transplant_NN until_IN the_DT date_NN of_IN
          death_NN ,_, censored_VBN for_IN loss_NN to_TO follow-up_JJ or_CC the_DT end_NN of_IN the_DT
          study_NN ._. The_DT end_NN of_IN the_DT study_NN period_NN was_VBD considered_VBN April_NNP
          2000_CD for_IN this_DT measurement_NN ._. The_DT patient_NN survival_NN
          probabilities_NNS were_VBD estimated_VBN by_IN using_VBG the_DT Life_NNP Tables_NNP and_CC
          Kaplan_NNP Meier_NNP method_NN ._.
        
        
          Statistical_NNP Analysis_NNP
          All_DT analyses_NNS were_VBD performed_VBN using_VBG SPSS_NNP 9_CD ._. 0_CD TM_NNP (_( SPSS_NNP ,_,
          Inc_NNP ._. ,_, Chicago_NNP ,_, IL_NNP )_) ._. Files_NNP were_VBD merged_VBN and_CC converted_VBN to_TO
          SPSS_NNP files_NNS using_VBG DBMS_NNP /_NN Copy_NNP (_( Conceptual_NNP Software_NNP ,_, Houston_NNP ,_,
          TX_NNP )_) ._. Univariate_NNP analysis_NN was_VBD performed_VBN with_IN Chi-square_NNP
          testing_NN for_IN categorical_JJ variables_NNS (_( Fisher_NNP 's_POS exact_JJ test_NN
          was_VBD used_VBN for_IN violations_NNS of_IN Cochran_NNP 's_POS assumptions_NNS )_) and_CC
          Student_NNP 's_POS two-sided_JJ t-test_JJ for_IN continuous_JJ variables_NNS (_( the_DT
          Wilcoxon_NNP signed_VBD rank_NN test_NN was_VBD used_VBN for_IN variables_NNS without_IN
          a_DT Gaussian_NNP distribution_NN )_) ._. Linear_NNP regression_NN analysis_NN was_VBD
          used_VBN to_TO assess_VB trends_NNS over_IN time_NN ,_, with_IN adjusted_VBN residuals_NNS
          inspected_VBN to_TO verify_VB the_DT appropriateness_NN of_IN the_DT regression_NN
          technique_NN ._. Variables_NNP with_IN p_NN <_NN 0_CD ._. 10_CD in_IN univariate_NN
          analysis_NN for_IN a_DT relationship_NN with_IN development_NN of_IN
          hospitalization_NN for_IN diabetic_JJ ketoacidosis_NNS were_VBD entered_VBN
          into_IN multivariate_NN analysis_NN as_IN covariates_NNS ._. Kaplan-_NNP Meier_NNP
          analysis_NN was_VBD used_VBN to_TO construct_VB survival_NN plots_NNS of_IN time_NN to_TO
          hospitalized_VBN diabetic_JJ ketoacidosis_NNS or_CC hyperglycemic_JJ
          hyperosmolar_NN syndrome_NN after_IN renal_JJ transplantation_NN ._.
          Log-log_NNP plots_NNS were_VBD inspected_VBN to_TO assess_VB for_IN
          proportionality_NN of_IN hazards_NNS over_IN time_NN at_IN the_DT mean_NN of_IN each_DT
          significant_JJ covariate_NN ._. Because_IN the_DT majority_NN of_IN patients_NNS
          were_VBD censored_VBN (_( did_VBD not_RB experience_VB the_DT primary_JJ outcome_NN )_)
          during_IN the_DT study_NN period_NN ,_, stepwise_NN Cox_NNP Regression_NNP
          (_( likelihood_NN ratio_NN method_NN )_) was_VBD used_VBN to_TO model_VB factors_NNS
          associated_VBN with_IN time_NN to_TO hospitalized_VBN diabetic_JJ
          ketoacidosis_NNS or_CC hyperglycemic_JJ hyperosmolar_NN syndrome_NN ,_,
          controlling_VBG for_IN covariates_NNS listed_VBN above_IN ._. For_IN all_DT risk_NN
          factor_NN analysis_NN reported_VBD in_IN the_DT present_JJ study_NN ,_, only_RB the_DT
          first_JJ hospitalization_NN for_IN diabetic_JJ ketoacidosis_NNS or_CC
          hyperglycemic_JJ hyperosmolar_NN syndrome_NN ,_, respectively_RB ,_,
          occurring_VBG during_IN the_DT study_NN period_NN was_VBD analyzed_VBN (_( one_CD
          hospitalization_NN per_IN patient_NN )_) ._. The_DT association_NN of_IN
          hospitalized_VBN diabetic_JJ ketoacidosis_NNS or_CC hyperglycemic_JJ
          hyperosmolar_NN syndrome_NN was_VBD assessed_VBN using_VBG Cox_NNP
          non-proportional_JJ hazards_NNS regression_NN ,_, with_IN times_NNS after_IN
          hospitalization_NN for_IN diabetic_JJ ketoacidosis_NNS coded_VBN as_IN 1_CD and_CC
          all_DT other_JJ times_NNS as_IN 0_CD ,_, as_RB previously_RB reported_VBD ._. [_NN 15_CD ]_NN
          Tacrolimus_NNP was_VBD introduced_VBN into_IN clinical_JJ practice_NN more_RBR
          recently_RB than_IN cyclosporine_NN ._. This_DT could_MD have_VB resulted_VBN in_IN
          bias_NN due_JJ to_TO the_DT shorter_JJR potential_JJ follow-up_JJ for_IN patients_NNS
          taking_VBG cyclosporine_NN ,_, leading_VBG to_TO unequal_JJ counting_NN of_IN more_RBR
          recent_JJ hospitalizations_NNS for_IN diabetic_JJ ketoacidosis_NNS in_IN
          patients_NNS who_WP used_VBD tacrolimus_JJ ._. In_IN addition_NN ,_, since_IN the_DT rate_NN
          of_IN diabetic_JJ ketoacidosis_NNS or_CC hyperglycemic_JJ hyperosmolar_NN
          syndrome_NN may_MD have_VB changed_VBN in_IN more_RBR recent_JJ years_NNS of_IN the_DT
          study_NN ,_, temporal_JJ bias_NN could_MD have_VB arisen_VBN despite_IN adjustment_NN
          for_IN year_NN of_IN transplant_NN ._. Therefore_RB ,_, additional_JJ analysis_NN
          was_VBD performed_VBN limited_VBN to_TO patients_NNS who_WP were_VBD transplanted_VBN
          on_IN or_CC after_IN 1_CD January_NNP ,_, 1996_CD ._.
        
      
      
        Results_NNS
        There_EX were_VBD 42_CD ,_, 096_CD solitary_JJ renal_JJ transplant_NN recipients_NNS
        in_IN the_DT United_NNP States_NNPS Renal_NNP Data_NNP System_NNP transplanted_VBN from_IN 1_CD
        July_NNP 1994_CD to_TO 30_CD June_NNP 1998_CD ,_, of_IN whom_WP 39_CD ,_, 628_CD had_VBD data_NNS complete_JJ
        enough_RB to_TO calculate_VB survival_NN times_NNS ._. The_DT most_RBS recent_JJ
        hospitalization_NN date_NN was_VBD December_NNP 31_CD ,_, 1999_CD ._. The_DT most_RBS recent_JJ
        date_NN of_IN death_NN was_VBD April_NNP 2000_CD ._. Mean_VB follow-up_JJ was_VBD 1_CD ._. 89_CD Â±_NN
        1_CD ._. 15_CD years_NNS (_( median_JJ ,_, 1_CD ._. 91_CD years_NNS )_) ._. Of_IN these_DT ,_, 428_CD recipients_NNS
        were_VBD hospitalized_VBN with_IN a_DT primary_JJ discharge_NN diagnosis_NN of_IN
        diabetic_JJ ketoacidosis_NNS with_IN 760_CD total_JJ hospitalizations_NNS ._. 115_CD
        recipients_NNS were_VBD hospitalized_VBN with_IN a_DT primary_JJ discharge_NN
        diagnosis_NN of_IN hyperglycemic_JJ hyperosmolar_NN syndrome_NN with_IN 122_CD
        total_JJ hospitalizations_NNS ._. The_DT most_RBS common_JJ secondary_JJ discharge_NN
        diagnosis_NN for_IN both_DT diabetic_JJ ketoacidosis_NNS and_CC hyperglycemic_JJ
        hyperosmolar_NN syndrome_NN was_VBD kidney_NN replaced_VBN by_IN transplant_NN ,_,
        and_CC secondary_JJ diagnoses_NNS did_VBD not_RB reveal_VB a_DT preponderance_NN of_IN
        conditions_NNS suggesting_VBG an_DT underlying_VBG condition_NN leading_VBG to_TO
        hospitalization_NN ._. Rates_NNS of_IN diabetic_JJ ketoacidosis_NNS by_IN history_NN
        of_IN diabetes_NN at_IN the_DT time_NN of_IN listing_NN are_VBP shown_VBN in_IN Table_NNP 1_CD ._.
        Characteristics_NNP of_IN the_DT study_NN population_NN ,_, as_RB well_RB as_IN risk_NN
        factors_NNS for_IN diabetic_JJ ketoacidosis_NNS for_IN the_DT entire_JJ cohort_NN and_CC
        for_IN recipients_NNS without_IN a_DT history_NN of_IN diabetes_NN at_IN the_DT time_NN of_IN
        listing_NN are_VBP shown_VBN in_IN Table_NNP 2_CD ._. As_IN previously_RB reported_VBN ,_, the_DT
        use_NN of_IN tacrolimus_JJ rose_VBD steadily_RB during_IN the_DT study_NN period_NN ,_,
        accounting_NN for_IN 5_CD ._. 2_CD %_NN of_IN all_DT calcineurin_NN inhibitor_NN use_NN in_IN
        1994_CD ,_, 5_CD ._. 9_CD %_NN in_IN 1995_CD ,_, 12_CD ._. 1_LS %_NN in_IN 1996_CD ,_, 17_CD ._. 5_LS %_NN in_IN 1997_CD ,_, and_CC 20_CD ._. 3_LS %_NN
        in_IN 1998_CD ._. The_DT three-year_JJ incidence_NN of_IN de_IN novo_NN diabetic_JJ
        ketoacidosis_NNS was_VBD 1_CD ._. 56_CD %_NN in_IN patients_NNS using_VBG tacrolimus_JJ vs_NNS ._.
        0_CD ._. 35_CD %_NN in_IN patients_NNS using_VBG cyclosporine_NN ._. However_RB ,_, there_EX were_VBD
        noteworthy_JJ temporal_JJ trends_NNS during_IN the_DT time_NN of_IN the_DT study_NN ,_,
        although_IN none_NN were_VBD statistically_RB significant_JJ ._. As_IN shown_VBN in_IN
        Figure_NN 1_CD ,_, there_EX was_VBD an_DT increase_NN in_IN the_DT rate_NN of_IN both_DT all_DT
        cases_NNS of_IN diabetic_JJ ketoacidosis_NNS and_CC de_IN novo_NN diabetic_JJ
        ketoacidosis_NNS during_IN the_DT years_NNS of_IN the_DT study_NN ._. However_RB ,_, an_DT
        opposite_JJ trend_NN was_VBD seen_VBN in_IN de_IN novo_NN diabetic_JJ ketoacidosis_NNS in_IN
        tacrolimus_JJ users_NNS ,_, Figure_NN 2_CD ._. As_IN shown_VBN ,_, the_DT rate_NN of_IN de_IN novo_NN
        diabetic_JJ ketoacidosis_NNS decreased_VBD sharply_RB among_IN tacrolimus_JJ
        users_NNS ,_, while_IN the_DT rate_NN of_IN total_JJ diabetic_JJ ketoacidosis_NNS did_VBD
        not_RB change_VB ._. Similar_JJ data_NNS for_IN hyperglycemic_JJ hyperosmolar_NN
        syndrome_NN are_VBP shown_VBN in_IN figures_NNS 3_CD ,_, 4_CD ._. In_IN contrast_NN ,_, there_EX were_VBD
        no_DT clear_JJ trends_NNS over_IN time_NN ,_, although_IN rates_NNS for_IN the_DT year_NN 1998_CD
        appeared_VBD disproportionately_RB high_JJ ._.
        The_DT mean_JJ age_NN of_IN patients_NNS hospitalized_VBN for_IN diabetic_JJ
        ketoacidosis_NNS was_VBD 41_CD ._. 4_LS Â±_NN 11_CD ._. 1_LS years_NNS vs_NNS ._. 43_CD ._. 4_LS Â±_NN 14_CD ._. 9_CD years_NNS
        for_IN recipients_NNS not_RB hospitalized_VBN for_IN diabetic_JJ ketoacidosis_NNS ,_,
        p_NN =_SYM 0_CD ._. 006_CD by_IN student_NN 's_POS t-test_JJ (_( equal_JJ variances_NNS assumed_VBD )_) ._.
        The_DT mean_NN BMI_NNP of_IN patients_NNS hospitalized_VBN for_IN hyperglycemic_JJ
        hyperosmolar_NN syndrome_NN was_VBD 24_CD ._. 4_LS Â±_NN 4_CD ._. 5_CD kg_NN /_NN m_NN 2_CD vs_NNS ._. 25_CD ._. 2_LS Â±_NN 5_CD ._. 3_CD
        kg_NN /_NN m_NN 2_CD for_IN recipients_NNS not_RB hospitalized_VBN for_IN hyperglycemic_JJ
        hyperosmolar_NN syndrome_NN ,_, p_NN =_SYM 0_CD ._. 008_CD by_IN student_NN 's_POS t-test_JJ ._. Of_IN
        African_NNP American_JJ recipients_NNS ,_, 1_CD ._. 6_CD %_NN were_VBD hospitalized_VBN for_IN
        diabetic_JJ ketoacidosis_NNS during_IN the_DT study_NN period_NN vs_NNS ._. 0_CD ._. 8_CD %_NN of_IN
        recipients_NNS of_IN other_JJ races_NNS (_( p_NN <_NN 0_CD ._. 001_CD by_IN Chi_NNP Square_NNP )_) ,_, and_CC
        of_IN patients_NNS hospitalized_VBN for_IN diabetic_JJ ketoacidosis_NNS ,_, 37_CD %_NN
        were_VBD African_NNP American_NNP ,_, vs_NNS ._. 23_CD ._. 1_LS %_NN of_IN patients_NNS not_RB
        hospitalized_VBN for_IN diabetic_JJ ketoacidosis_NNS (_( p_NN <_NN 0_CD ._. 001_CD by_IN Chi_NNP
        Square_NNP )_) ._.
        In_IN Cox_NNP Regression_NNP analysis_NN ,_, factors_NNS that_WDT were_VBD positively_RB
        associated_VBN with_IN total_JJ rates_NNS of_IN hospitalized_VBN diabetic_JJ
        ketoacidosis_NNS were_VBD younger_JJR age_NN ,_, graft_NN loss_NN ,_, African_NNP American_JJ
        race_NN ,_, more_RBR recent_JJ year_NN of_IN transplant_NN ,_, lower_JJR body_NN mass_NN
        index_NN ,_, and_CC female_JJ gender_NN ._. There_EX were_VBD no_DT significant_JJ
        interactions_NNS between_IN race_NN ,_, gender_NN ,_, hepatitis_NNP C_NNP status_NN ,_, or_CC
        tacrolimus_JJ use_NN ._. For_IN de_IN novo_NN diabetic_JJ ketoacidosis_NNS ,_, gender_NN
        and_CC graft_NN loss_NN were_VBD not_RB significant_JJ ,_, and_CC cadaver_NN donor_NN was_VBD
        significant_JJ ._. Recipients_NNP who_WP used_VBD maintenance_NN tacrolimus_JJ
        (_( adjusted_VBN hazard_NN ratio_NN ,_, 2_CD ._. 27_CD ,_, 95_CD %_NN confidence_NN interval_NN ,_,
        1_CD ._. 52_CD -_: 3_CD ._. 38_CD ,_, p_NN =_SYM 0_CD ._. 001_CD )_) had_VBD a_DT higher_JJR risk_NN of_IN de_IN novo_NN diabetic_JJ
        ketoacidosis_NNS ,_, compared_VBN to_TO recipients_NNS who_WP used_VBD cyclosporine_NN ._.
        Significance_NN persisted_VBD even_RB in_IN analysis_NN limited_VBN to_TO patients_NNS
        who_WP were_VBD transplanted_VBN on_IN or_CC after_IN 1_CD Jan_NNP 1996_CD (_( adjusted_VBN
        hazard_NN ratio_NN for_IN tacrolimus_JJ ,_, 1_CD ._. 75_CD ,_, 95_CD %_NN confidence_NN interval_NN ,_,
        1_CD ._. 06_CD -_: 2_CD ._. 89_CD ,_, p_NN =_SYM 0_CD ._. 03_CD )_) ._. However_RB ,_, the_DT pattern_NN of_IN risk_NN over_IN
        time_NN violated_VBD the_DT proportional_JJ hazards_NNS assumption_NN ,_, since_IN
        there_EX was_VBD a_DT substantially_RB greater_JJR risk_NN of_IN de_IN novo_NN diabetic_JJ
        ketoacidosis_NNS among_IN tacrolimus_JJ users_NNS starting_VBG at_IN two_CD years_NNS
        after_IN transplant_NN ,_, coinciding_VBG with_IN the_DT introduction_NN of_IN
        tacrolimus_JJ into_IN clinical_JJ practice_NN ._. Therefore_RB ,_, analysis_NN was_VBD
        also_RB performed_VBN limited_VBN to_TO patients_NNS transplanted_VBN on_IN or_CC after_IN
        1_CD July_NNP 1996_CD ,_, limited_VBN to_TO two_CD years_NNS of_IN follow-up_JJ ._. In_IN this_DT
        analysis_NN ,_, tacrolimus_JJ was_VBD not_RB significantly_RB associated_VBN with_IN
        de_IN novo_NN diabetic_JJ ketoacidosis_NNS ,_, p_NN =_SYM 0_CD ._. 10_CD ,_, adjusted_VBN hazard_NN
        ratio_NN ,_, 2_CD ._. 11_CD ,_, 95_CD %_NN CI_NNP ,_, 0_CD ._. 86_CD -_: 5_CD ._. 21_CD ._. In_IN analysis_NN including_VBG
        patients_NNS with_IN diabetes_NN during_IN the_DT entire_JJ study_NN period_NN ,_,
        tacrolimus_JJ use_NN was_VBD only_RB significantly_RB associated_VBN with_IN
        diabetic_JJ ketoacidosis_NNS in_IN recipients_NNS of_IN cadaver_NN kidneys_NNS
        (_( adjusted_VBN hazard_NN ratio_NN ,_, 2_CD ._. 15_CD ,_, 95_CD %_NN CI_NNP ,_, 1_CD ._. 10_CD -_: 4_CD ._. 23_CD ,_, p_NN =_SYM
        0_CD ._. 03_CD )_) ._.
        The_DT mean_JJ age_NN of_IN patients_NNS hospitalized_VBN for_IN hyperglycemic_JJ
        hyperosmolar_NN syndrome_NN was_VBD 46_CD ._. 2_LS Â±_NN 13_CD ._. 0_CD years_NNS vs_NNS ._. 43_CD ._. 4_LS Â±_NN 14_CD ._. 9_CD
        years_NNS for_IN recipients_NNS not_RB hospitalized_VBN for_IN hyperglycemic_JJ
        hyperosmolar_NN syndrome_NN ,_, p_NN =_SYM 0_CD ._. 04_CD by_IN student_NN 's_POS t-test_JJ (_( equal_JJ
        variances_NNS assumed_VBD )_) ._. The_DT mean_NN BMI_NNP of_IN patients_NNS hospitalized_VBN
        for_IN hyperglycemic_JJ hyperosmolar_NN syndrome_NN was_VBD 26_CD ._. 6_CD Â±_NN 4_CD ._. 9_CD kg_NN /_NN m_NN
        2_CD vs_NNS ._. 25_CD ._. 2_LS Â±_NN 5_CD ._. 3_CD kg_NN /_NN m_NN 2_CD for_IN recipients_NNS not_RB hospitalized_VBN for_IN
        hyperglycemic_JJ hyperosmolar_NN syndrome_NN ,_, p_NN =_SYM 0_CD ._. 03_CD by_IN student_NN 's_POS
        t-test_JJ ._. Of_IN recipients_NNS who_WP were_VBD seropositive_JJ for_IN hepatitis_NNP
        C_NNP ,_, 0_CD ._. 8_CD %_NN were_VBD hospitalized_VBN for_IN hyperglycemic_JJ hyperosmolar_NN
        syndrome_NN during_IN the_DT study_NN period_NN vs_NNS ._. 0_CD ._. 2_CD %_NN of_IN HCV_NNP negative_JJ
        recipients_NNS (_( p_NN <_NN 0_CD ._. 001_CD by_IN Chi_NNP Square_NNP )_) ,_, and_CC of_IN patients_NNS
        hospitalized_VBN for_IN hyperglycemic_JJ hyperosmolar_NN syndrome_NN ,_, 16_CD ._. 5_LS %_NN
        were_VBD HCV_NNP positive_NN ,_, vs_NNS ._. 5_CD ._. 7_CD %_NN of_IN patients_NNS not_RB hospitalized_VBN
        for_IN hyperglycemic_JJ hyperosmolar_NN syndrome_NN (_( p_NN <_NN 0_CD ._. 001_CD by_IN
        Chi_NNP Square_NNP )_) ._. Of_IN African_NNP American_JJ recipients_NNS ,_, 0_CD ._. 7_CD %_NN were_VBD
        hospitalized_VBN for_IN hyperglycemic_JJ hyperosmolar_NN syndrome_NN during_IN
        the_DT study_NN period_NN vs_NNS ._. 0_CD ._. 1_CD %_NN of_IN recipients_NNS of_IN other_JJ races_NNS (_( p_NN
        <_NN 0_CD ._. 001_CD by_IN Chi_NNP Square_NNP )_) ,_, and_CC of_IN patients_NNS hospitalized_VBN for_IN
        hyperglycemic_JJ hyperosmolar_NN syndrome_NN ,_, 60_CD %_NN were_VBD African_NNP
        American_NNP ,_, vs_NNS ._. 23_CD ._. 1_LS %_NN of_IN patients_NNS not_RB hospitalized_VBN for_IN
        hyperglycemic_JJ hyperosmolar_NN syndrome_NN (_( p_NN <_NN 0_CD ._. 001_CD by_IN Chi_NNP
        Square_NNP )_) ._. There_EX was_VBD considerable_JJ overlap_VB between_IN risk_NN
        factors_NNS for_IN diabetic_JJ ketoacidosis_NNS and_CC hyperglycemic_JJ
        hyperosmolar_NN syndrome_NN except_IN for_IN the_DT significance_NN of_IN
        recipient_JJ hepatitis_NNP C_NNP positive_JJ serology_NN and_CC the_DT lack_NN of_IN
        significance_NN of_IN female_JJ gender_NN (_( Table_NNP 4_LS )_) ._. There_EX was_VBD no_DT
        significant_JJ interaction_NN between_IN recipient_JJ hepatitis_NNP C_NNP
        serology_NN and_CC tacrolimus_JJ use_NN ._. There_EX was_VBD no_DT association_NN
        between_IN hyperglycemic_JJ hyperosmolar_NN syndrome_NN and_CC BMI_NNP ,_, either_CC
        as_IN a_DT continuous_JJ or_CC as_IN a_DT categorical_JJ variable_NN ._. No_DT
        independent_JJ risk_NN factors_NNS for_IN de_IN novo_NN hyperglycemic_JJ
        hyperosmolar_NN syndrome_NN were_VBD identified_VBN ,_, and_CC are_VBP therefore_RB
        not_RB presented_VBN in_IN tabular_NN form_NN ._.
        In-hospital_NNP mortality_NN was_VBD 1_CD ._. 9_CD %_NN for_IN patients_NNS with_IN
        diabetic_JJ ketoacidosis_NNS and_CC 0_CD ._. 9_CD %_NN for_IN patients_NNS with_IN
        hyperglycemic_JJ hyperosmolar_NN syndrome_NN ._. Mortality_NNP after_IN
        diabetic_JJ ketoacidosis_NNS is_VBZ shown_VBN in_IN Figure_NN 5_CD ._. The_DT risk_NN of_IN
        mortality_NN after_IN hospitalization_NN for_IN diabetic_JJ ketoacidosis_NNS
        was_VBD fairly_RB constant_JJ over_IN time_NN ._. Hospitalized_NNP diabetic_JJ
        ketoacidosis_NNS was_VBD independently_RB associated_VBN with_IN increased_VBN
        mortality_NN in_IN Cox_NNP non-proportional_JJ hazards_NNS regression_NN
        analysis_NN ,_, adjusted_VBN hazard_NN ratio_NN =_SYM 2_CD ._. 44_CD ,_, 95_CD %_NN CI_NNP ,_, 2_CD ._. 10_CD -_: 2_CD ._. 85_CD ,_,
        p_NN <_NN 0_CD ._. 0001_CD ._. Causes_NNP of_IN death_NN were_VBD missing_VBG or_CC unknown_JJ for_IN
        57_CD ._. 3_LS %_NN of_IN patients_NNS with_IN diabetic_JJ ketoacidosis_NNS ._. The_DT leading_VBG
        specified_VBN causes_NNS of_IN death_NN were_VBD cardiac_JJ arrest_NN of_IN unknown_JJ
        cause_NN (_( 8_CD ._. 5_LS %_NN )_) ,_, acute_JJ myocardial_NN infraction_NN (_( 5_CD %_NN )_) ,_, sepsis_NN
        (_( 4_CD %_NN )_) ,_, and_CC atherosclerotic_JJ heart_NN disease_NN (_( 4_CD %_NN )_) ._.
        Similar_JJ to_TO the_DT linear_JJ risk_NN of_IN mortality_NN after_IN diabetic_JJ
        ketoacidosis_NNS ,_, the_DT risk_NN of_IN mortality_NN after_IN hyperglycemic_JJ
        hyperosmolar_NN syndrome_NN was_VBD constant_JJ over_IN time_NN (_( Figure_NN 6_CD )_) ._.
        Hospitalization_NNP for_IN hyperglycemic_JJ hyperosmolar_NN syndrome_NN was_VBD
        independently_RB associated_VBN with_IN increased_VBN mortality_NN in_IN Cox_NNP
        non-proportional_JJ hazards_NNS regression_NN analysis_NN ,_, adjusted_VBN
        hazard_NN ratio_NN =_SYM 1_CD ._. 87_CD ,_, 95_CD %_NN CI_NNP ,_, 1_CD ._. 22_CD -_: 2_CD ._. 88_CD ,_, p_NN =_SYM 0_CD ._. 004_CD ._. Causes_NNP
        of_IN death_NN were_VBD missing_VBG or_CC unknown_JJ for_IN 45_CD ._. 5_LS %_NN of_IN patients_NNS with_IN
        hyperglycemic_JJ hyperosmolar_NN syndrome_NN ._. The_DT leading_VBG cause_NN of_IN
        death_NN in_IN patients_NNS hospitalized_VBN for_IN hyperglycemic_JJ
        hyperosmolar_NN syndrome_NN was_VBD acute_JJ myocardial_NN infarction_NN
        (_( 18_CD %_NN )_) ,_, cardiac_JJ arrest_NN of_IN unknown_JJ cause_NN (_( 13_CD %_NN )_) ,_, and_CC sepsis_NN
        (_( 9_CD %_NN )_) ._.
      
      
        Discussion_NNP
        The_DT present_JJ study_NN showed_VBD that_IN renal_JJ transplant_NN
        recipients_NNS had_VBD a_DT rate_NN of_IN diabetic_JJ ketoacidosis_NNS of_IN 33_CD ._. 2_LS /_NN 1000_CD
        person_NN years_NNS in_IN recipients_NNS a_DT history_NN of_IN diabetes_NN as_IN a_DT
        comorbid_NN condition_NN and_CC 1_CD ._. 9_CD /_NN 1000_CD person_NN years_NNS in_IN patients_NNS
        without_IN a_DT prior_JJ history_NN of_IN diabetes_NN (_( measured_VBN as_IN total_JJ
        hospitalizations_NNS for_IN comparison_NN with_IN other_JJ reports_NNS )_) ._. In_IN
        contrast_NN ,_, the_DT estimated_VBN annual_JJ incidence_NN of_IN diabetic_JJ
        ketoacidosis_NNS in_IN the_DT general_JJ population_NN was_VBD 4_CD ._. 6_CD -_: 8_CD episodes_NNS
        per_IN 1000_CD diabetic_JJ subjects_NNS ._. [_NN 16_CD ]_NN In_IN the_DT general_JJ
        population_NN ,_, the_DT rate_NN of_IN diabetic_JJ ketoacidosis_NNS episodes_NNS as_IN a_DT
        primary_JJ hospitalization_NN diagnosis_NN was_VBD 0_CD ._. 3_CD /_NN 1000_CD patients_NNS ,_,
        and_CC the_DT rate_NN of_IN hyperglycemic_JJ hyperosmolar_NN syndrome_NN
        episodes_NNS was_VBD 0_CD ._. 04_CD /_NN 1000_CD in_IN 1997_CD (_( rates_NNS stratified_JJ for_IN
        patients_NNS with_IN diabetes_NN were_VBD not_RB available_JJ )_) ._. [_NN 17_CD ]_NN Although_IN
        statistical_JJ comparison_NN could_MD not_RB be_VB performed_VBN due_JJ to_TO the_DT
        much_RB higher_JJR rate_NN of_IN diabetes_NN among_IN renal_JJ transplant_NN
        recipients_NNS than_IN in_IN the_DT general_JJ population_NN ,_, the_DT rates_NNS of_IN
        diabetic_JJ ketoacidosis_NNS and_CC hyperglycemic_JJ hyperosmolar_NN
        syndrome_NN in_IN renal_JJ transplant_NN recipients_NNS appear_VBP to_TO be_VB
        substantially_RB higher_JJR than_IN for_IN either_DT diabetic_JJ patients_NNS or_CC
        for_IN the_DT general_JJ population_NN ,_, after_IN excluding_VBG patients_NNS with_IN
        combined_VBN kidney-pancreas_JJ transplants_NNS ._.
        Certain_JJ risk_NN factors_NNS were_VBD common_JJ to_TO both_DT the_DT total_JJ risk_NN
        of_IN diabetic_JJ ketoacidosis_NNS and_CC the_DT risk_NN of_IN de_IN novo_NN diabetic_JJ
        ketoacidosis_NNS (_( diabetic_JJ ketoacidosis_NNS occurring_VBG in_IN patients_NNS
        without_IN a_DT prior_RB known_VBN history_NN of_IN diabetes_NN )_) ._. Consistent_NNP with_IN
        the_DT general_JJ population_NN ,_, African_NNP Americans_NNPS were_VBD at_IN higher_JJR
        risk_NN of_IN diabetic_JJ ketoacidosis_NNS than_IN non-_NN African_NNP Americans_NNPS
        (_( Hispanic_JJ race_NN was_VBD only_RB introduced_VBN into_IN the_DT database_NN
        recently_RB )_) ._. [_NN 18_CD 19_CD 20_CD 21_CD ]_NN The_DT higher_JJR risk_NN of_IN African_NNP
        Americans_NNPS was_VBD independent_JJ of_IN other_JJ factors_NNS in_IN the_DT database_NN ,_,
        such_JJ as_IN body_NN mass_NN index_NN ,_, graft_NN loss_NN ,_, rejection_NN episodes_NNS or_CC
        employment_NN status_NN ._. Despite_IN adjustment_NN for_IN these_DT factors_NNS ,_,
        socioeconomic_JJ factors_NNS could_MD certainly_RB not_RB be_VB excluded_VBN ,_, and_CC
        have_VBP been_VBN implicated_VBN in_IN prior_JJ studies_VBZ ._. Similarly_RB ,_, low_JJ body_NN
        mass_NN index_NN was_VBD associated_VBN with_IN diabetic_JJ ketoacidosis_NNS in_IN
        either_DT situation_NN (_( in_IN contrast_NN to_TO the_DT association_NN of_IN high_JJ
        body_NN mass_NN with_IN the_DT increased_VBN risk_NN of_IN type_NN II_NNP diabetes_NN )_) ._. [_NN
        22_CD ]_NN However_RB ,_, differences_NNS in_IN gender_NN and_CC graft_NN loss_NN were_VBD not_RB
        associated_VBN with_IN de_IN novo_NN diabetic_JJ ketoacidosis_NNS ._. Each_DT of_IN
        these_DT may_MD reflect_VB risk_NN factors_NNS for_IN diabetes_NN in_IN the_DT general_JJ
        population_NN ._. Conversely_RB ,_, donor_NN type_NN and_CC use_NN of_IN maintenance_NN
        tacrolimus_JJ were_VBD only_RB associated_VBN with_IN de_IN novo_NN diabetic_JJ
        ketoacidosis_NNS ._. The_DT increased_VBN risk_NN of_IN cadaver_NN donor_NN type_NN
        could_MD be_VB related_VBN to_TO medication_NN use_NN ._. The_DT relatively_RB high_JJ
        rate_NN of_IN "_'' de_IN novo_NN "_'' diabetic_JJ ketoacidosis_NNS (_( diabetic_JJ
        ketoacidosis_NNS occurring_VBG in_IN patients_NNS who_WP did_VBD not_RB have_VB a_DT known_VBN
        diagnosis_NN of_IN diabetes_NN at_IN the_DT time_NN of_IN transplant_NN )_) could_MD
        represent_VB drug-associated_JJ diabetic_JJ ketoacidosis_NNS ,_, which_WDT has_VBZ
        infrequently_RB been_VBN reported_VBN with_IN the_DT use_NN of_IN both_DT tacrolimus_JJ
        and_CC cyclosporine_NN ._. [_NN 3_CD ]_NN Previous_JJ case_NN series_NN did_VBD not_RB have_VB
        sufficient_JJ sample_NN size_NN to_TO determine_VB competing_VBG risks_NNS between_IN
        calcineurin_NN inhibitors_NNS ,_, but_CC the_DT present_JJ study_NN would_MD suggest_VB
        the_DT risk_NN is_VBZ greater_JJR with_IN tacrolimus_JJ ._. Because_IN of_IN rapid_JJ
        changes_NNS in_IN the_DT use_NN of_IN tacrolimus_JJ during_IN the_DT study_NN period_NN ,_,
        as_IN indicated_VBN above_IN ,_, conclusions_NNS should_MD be_VB limited_JJ ._. We_PRP would_MD
        certainly_RB caution_VB any_DT interpretation_NN of_IN tacrolimus_JJ use_NN
        since_IN there_EX were_VBD substantial_JJ temporal_JJ trends_NNS during_IN the_DT
        study_NN ,_, and_CC tacrolimus_JJ was_VBD not_RB approved_VBN by_IN the_DT FDA_NNP for_IN use_NN
        in_IN kidney_NN transplantation_NN until_IN 1997_CD ._. As_IN indicated_VBD ,_, in_IN our_PRP$
        analysis_NN limited_VBN to_TO that_DT time_NN span_NN ,_, tacrolimus_JJ was_VBD not_RB
        significantly_RB associated_VBN with_IN increased_VBN risk_NN of_IN diabetic_JJ
        ketoacidosis_NNS ._.
        Almost_RB all_DT reports_NNS of_IN post-transplant_JJ diabetes_NN mellitus_JJ
        in_IN the_DT medical_JJ literature_NN have_VBP either_CC concerned_VBN type_NN II_NNP
        diabetes_NN or_CC have_VBP not_RB specified_VBN by_IN type_NN ._. Therefore_RB ,_, reported_VBD
        risk_NN factors_NNS such_JJ as_IN obesity_NN ,_, cumulative_JJ prednisone_NN use_NN ,_,
        and_CC hepatitis_NNP C_NNP status_NN would_MD not_RB be_VB expected_VBN to_TO affect_VB the_DT
        risk_NN of_IN diabetic_JJ ketoacidosis_NNS ,_, consistent_JJ with_IN reports_NNS in_IN
        the_DT general_JJ population_NN ._. This_DT is_VBZ in_IN contrast_NN to_TO
        hyperglycemic_JJ hyperosmolar_NN syndrome_NN ,_, which_WDT would_MD be_VB
        expected_VBN to_TO occur_VB disproportionately_RB in_IN patients_NNS with_IN type_NN
        II_NNP diabetes_NN ._. While_IN older_JJR age_NN and_CC higher_JJR BMI_NNP were_VBD
        significant_JJ in_IN univariate_NN analysis_NN ,_, they_PRP were_VBD not_RB
        significant_JJ in_IN multivariate_NN analysis_NN ,_, while_IN the_DT
        significance_NN of_IN positive_JJ recipient_JJ hepatitis_NNP C_NNP serology_NN
        persisted_VBD ._. Use_NN of_IN diabetes_NN as_IN an_DT aggregate_JJ outcome_NN ,_,
        combining_VBG either_CC both_DT type_NN I_PRP and_CC type_NN II_NNP diabetes_NN ,_, or_CC
        combining_VBG diabetic_JJ ketoacidosis_NNS and_CC hyperglycemic_JJ
        hyperosmolar_NN syndrome_NN ,_, might_MD obscure_VB the_DT relationship_NN with_IN
        certain_JJ risk_NN factors_NNS if_IN the_DT associations_NNS were_VBD in_IN different_JJ
        directions_NNS (_( as_IN is_VBZ the_DT case_NN with_IN body_NN mass_NN index_NN ,_, for_IN
        example_NN :_: low_JJ body_NN mass_NN index_NN being_VBG associated_VBN with_IN type_NN I_PRP
        diabetes_NN ,_, and_CC high_JJ body_NN mass_NN being_VBG associated_VBN with_IN type_NN II_NNP
        diabetes_NN )_) ._. Use_NN of_IN such_JJ aggregate_JJ outcomes_NNS might_MD also_RB have_VB
        missed_VBN an_DT association_NN between_IN hyperglycemic_JJ hyperosmolar_NN
        syndrome_NN and_CC hepatitis_NNP C_NNP ._. The_DT present_JJ study_NN thus_RB provides_VBZ
        more_RBR indirect_JJ evidence_NN that_IN the_DT post-transplant_JJ diabetes_NN
        associated_VBN with_IN hepatitis_NNP C_NNP infection_NN is_VBZ predominantly_RB type_NN
        II_NNP diabetes_NN ,_, as_IN suggested_VBN in_IN other_JJ reports_NNS ._. [_NN 23_CD 24_CD ]_NN This_DT
        is_VBZ in_IN contrast_NN to_TO a_DT lack_NN of_IN association_NN between_IN hepatitis_NNP C_NNP
        seropositivity_NN and_CC diabetes_NN as_IN a_DT cause_NN of_IN renal_JJ failure_NN ,_, as_IN
        we_PRP have_VBP previously_RB reported_VBN ._. [_NN 25_CD ]_NN
        Nevertheless_RB ,_, the_DT increasing_VBG rate_NN of_IN diabetic_JJ
        ketoacidosis_NNS noted_VBD during_IN the_DT study_NN period_NN (_( Figure_NN 1_CD ,_, more_JJR
        marked_VBD for_IN total_JJ diabetic_JJ ketoacidosis_NNS than_IN de_IN novo_NN
        diabetic_JJ ketoacidosis_NNS )_) is_VBZ in_IN contrast_NN to_TO the_DT decreasing_VBG
        rate_NN of_IN de_IN novo_NN diabetic_JJ ketoacidosis_NNS and_CC stable_JJ rate_NN of_IN
        total_JJ diabetic_JJ ketoacidosis_NNS noted_VBD for_IN users_NNS of_IN tacrolimus_JJ
        (_( Figure_NN 2_LS )_) ._. While_IN this_DT information_NN is_VBZ necessarily_RB
        preliminary_JJ ,_, it_PRP suggests_VBZ the_DT possibility_NN that_WDT factors_NNS other_JJ
        than_IN tacrolimus_JJ use_NN may_MD be_VB responsible_JJ for_IN the_DT increasing_VBG
        rate_NN of_IN diabetic_JJ ketoacidosis_NNS noted_VBD during_IN the_DT study_NN ,_, which_WDT
        was_VBD independent_JJ of_IN all_DT other_JJ factors_NNS assessed_VBN ._. We_PRP did_VBD not_RB
        find_VB an_DT association_NN between_IN diabetic_JJ ketoacidosis_NNS and_CC viral_JJ
        infections_NNS other_JJ than_IN hepatitis_NNP C_NNP ,_, notably_RB cytomegalovirus_JJ ,_,
        nor_CC did_VBD we_PRP find_VBP an_DT association_NN between_IN diabetic_JJ
        ketoacidosis_NNS and_CC antibody_NN induction_NN therapy_NN ,_, which_WDT would_MD be_VB
        expected_VBN to_TO decrease_VB immunity_NN but_CC might_MD also_RB allow_VB for_IN a_DT
        greater_JJR propensity_NN to_TO viral_JJ infections_NNS ._. We_PRP can_MD only_RB point_VB
        to_TO another_DT recent_JJ report_NN by_IN Bhalla_NNP et_CC al_NN ,_, [_NN 26_CD ]_NN which_WDT
        found_VBD that_IN "_'' de_IN novo_NN "_'' post-transplant_JJ diabetes_NN mellitus_JJ
        (_( confirmed_VBN by_IN renal_JJ biopsy_NN )_) was_VBD much_RB more_RBR common_JJ and_CC much_RB
        more_RBR rapid_JJ in_IN onset_NN than_IN previously_RB suspected_VBN ,_, and_CC could_MD
        not_RB be_VB explained_VBN by_IN usual_JJ clinical_JJ predictors_NNS ,_, which_WDT is_VBZ
        quite_RB similar_JJ to_TO our_PRP$ findings_NNS ._. The_DT authors_NNS implicated_VBN
        "_'' novel_NN mechanisms_NNS "_'' as_IN the_DT reason_NN for_IN this_DT rapid_JJ increase_NN ._.
        Whether_IN this_DT represents_VBZ a_DT relationship_NN with_IN newly_RB
        appreciated_VBN viral_JJ infections_NNS ,_, such_JJ as_IN polyomavirus_JJ ,_, or_CC
        other_JJ factors_NNS is_VBZ presently_RB unknown_JJ ._.
        Both_DT diabetic_JJ ketoacidosis_NNS and_CC hyperglycemic_JJ
        hyperosmolar_NN syndrome_NN were_VBD associated_VBN with_IN an_DT increased_VBN
        risk_NN of_IN mortality_NN among_IN renal_JJ transplant_NN recipients_NNS ,_,
        consistent_JJ with_IN reports_NNS in_IN the_DT general_JJ population_NN ._. [_NN 27_CD 28_CD
        ]_NN If_IN anything_NN ,_, the_DT relative_JJ risk_NN associated_VBN with_IN diabetic_JJ
        ketoacidosis_NNS was_VBD greater_JJR than_IN that_DT for_IN hyperglycemic_JJ
        hyperosmolar_NN syndrome_NN ,_, somewhat_RB in_IN contrast_NN to_TO the_DT general_JJ
        population_NN ._. However_RB ,_, previous_JJ population_NN based_VBD reports_NNS have_VBP
        not_RB adjusted_VBN for_IN the_DT difference_NN in_IN age_NN of_IN presentation_NN for_IN
        this_DT differing_VBG conditions_NNS ._. Given_VBN the_DT limitations_NNS of_IN the_DT
        database_NN ,_, causes_NNS of_IN death_NN were_VBD primarily_RB cardiovascular_JJ and_CC
        not_RB infectious_JJ ,_, also_RB consistent_JJ with_IN the_DT general_JJ
        population_NN ._. [_NN 16_CD ]_NN
        There_EX are_VBP several_JJ limitations_NNS to_TO this_DT retrospective_NN
        study_NN ._. Findings_NNP are_VBP associative_JJ ,_, not_RB causative_JJ ,_, and_CC risk_NN
        cannot_NN be_VB assigned_VBN without_IN the_DT ability_NN to_TO control_VB for_IN other_JJ
        variables_NNS prospectively_RB during_IN the_DT course_NN of_IN the_DT study_NN ._. We_PRP
        could_MD not_RB assess_VB the_DT causes_NNS for_IN hospitalization_NN for_IN
        diabetic_JJ ketoacidosis_NNS or_CC hyperglycemic_JJ hyperosmolar_NN
        syndrome_NN ,_, or_CC how_WRB they_PRP were_VBD treated_VBN ,_, including_VBG the_DT use_NN of_IN
        insulin_NN ._. This_DT study_NN could_MD not_RB independently_RB verify_VB the_DT type_NN
        of_IN diabetes_NN ._. We_PRP could_MD not_RB assess_VB certain_JJ important_JJ risk_NN
        factors_NNS ,_, such_JJ as_IN nutritional_JJ status_NN ,_, the_DT use_NN of_IN alcohol_NN or_CC
        infection_NN ,_, with_IN hospitalized_VBN diabetic_JJ ketoacidosis_NNS or_CC
        hyperglycemic_JJ hyperosmolar_NN syndrome_NN ._. However_RB ,_, ICD-_NNP 9_CD coding_VBG
        for_IN determining_VBG rates_NNS of_IN medical_JJ conditions_NNS has_VBZ been_VBN used_VBN
        in_IN other_JJ published_VBN studies_NNS ,_, [_NN 29_CD ]_NN as_RB well_RB as_IN the_DT National_NNP
        Center_NNP for_IN Health_NNP Statistics_NNPS ._. http_NN :_: /_NN /_NN www_NN ._. cdc_NN ._. gov_NN /_NN nchsThe_NN
        current_JJ study_NN 's_POS limitation_NN to_TO hospitalized_VBN cases_NNS of_IN
        diabetic_JJ ketoacidosis_NNS and_CC hyperglycemic_JJ hyperosmolar_NN
        syndrome_NN would_MD tend_VB to_TO underestimate_NN the_DT frequency_NN of_IN these_DT
        conditions_NNS in_IN this_DT population_NN ._. However_RB ,_, these_DT conditions_NNS
        are_VBP almost_RB universally_RB managed_VBN by_IN hospitalization_NN in_IN the_DT
        United_NNP States_NNPS ._. Another_DT limitation_NN of_IN the_DT study_NN is_VBZ the_DT
        inability_NN to_TO track_VB whether_IN the_DT patients_NNS were_VBD subsequently_RB
        switched_VBN from_IN tacrolimus_JJ or_CC cyclosporine_NN during_IN the_DT course_NN
        of_IN the_DT present_JJ study_NN ._. However_RB ,_, reports_NNS of_IN conversion_NN from_IN
        cyclosporine_NN to_TO tacrolimus_JJ ,_, [_NN 30_CD 31_CD ]_NN which_WDT are_VBP most_RBS
        commonly_RB employed_VBN as_IN a_DT rescue_NN agent_NN for_IN refractory_JJ acute_JJ or_CC
        chronic_JJ rejection_NN or_CC cyclosporine_NN toxicity_NN ,_, suggest_VBP that_IN
        this_DT number_NN is_VBZ very_RB small_JJ ._. Similarly_RB ,_, conversion_NN from_IN
        tacrolimus_JJ to_TO cyclosporine_NN ,_, most_RBS commonly_RB due_JJ to_TO tacrolimus_JJ
        induced_VBN diabetes_NN ,_, by_IN published_VBN report_NN appears_VBZ to_TO be_VB even_RB
        rarer_NN ._. [_NN 32_CD ]_NN The_DT short_JJ followup_NN duration_NN of_IN the_DT study_NN may_MD
        also_RB be_VB a_DT limitation_NN ._. Strengths_NNP of_IN the_DT present_JJ analysis_NN
        include_VBP its_PRP$ large_JJ size_NN and_CC population-based_JJ character_NN ,_, and_CC
        relatively_RB complete_JJ capture_NN and_CC followup_NN ._.
        In_IN conclusion_NN ,_, rates_NNS of_IN diabetic_JJ ketoacidosis_NNS and_CC
        hyperglycemic_JJ hyperosmolar_NN syndrome_NN after_IN renal_JJ
        transplantation_NN were_VBD substantially_RB higher_RBR than_IN reported_VBD for_IN
        the_DT general_JJ population_NN ,_, whether_IN in_IN diabetic_JJ or_CC non-diabetic_JJ
        populations_NNS ._. These_DT rates_NNS appear_VBP to_TO be_VB increasing_VBG
        significantly_RB over_IN time_NN ,_, particularly_RB for_IN diabetic_JJ
        ketoacidosis_NNS ,_, even_RB as_IN the_DT risk_NN for_IN diabetic_JJ ketoacidosis_NNS in_IN
        patients_NNS treated_VBN with_IN tacrolimus_JJ is_VBZ decreasing_VBG
        significantly_RB ._. In_IN addition_NN ,_, we_PRP identified_VBD high-risk_JJ groups_NNS
        for_IN diabetic_JJ ketoacidosis_NNS ,_, de_IN novo_NN diabetic_JJ ketoacidosis_NNS
        and_CC hyperglycemic_JJ hyperosmolar_NN syndrome_NN after_IN renal_JJ
        transplantation_NN ,_, and_CC confirmed_VBD the_DT association_NN of_IN both_DT
        diabetic_JJ ketoacidosis_NNS and_CC hyperglycemic_JJ hyperosmolar_NN
        syndrome_NN with_IN increased_VBN mortality_NN after_IN renal_JJ
        transplantation_NN ._.
      
      
        Author_NN contributions_NNS
        KCA_NNP performed_VBD the_DT primary_JJ analysis_NN and_CC wrote_VBD the_DT first_JJ
        draft_NN of_IN the_DT manuscript_NN ,_, and_CC is_VBZ the_DT corresponding_JJ
        author_NN ._.
        VJB_NNP collaborated_VBD on_IN the_DT manuscript_NN providing_VBG expertise_NN
        on_IN the_DT primary_JJ subject_JJ matter_NN
        LYA_NNP supervised_VBD the_DT manuscript_NN and_CC is_VBZ a_DT world_NN expert_NN on_IN
        the_DT USRDS_NNP database_NN ,_, as_IN the_DT Program_NNP Director_NNP for_IN the_DT
        USRDS_NNP
        CMY_NNP developed_VBD the_DT original_JJ concept_NN for_IN the_DT manuscript_NN
        and_CC reviewed_VBD the_DT final_JJ version_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
    
  
